Clinical trial: ASIS for GAMMAGARD in Primary Immunodeficiency
Status: UNKNOWN
Conditions: Primary Immunodeficiency
Interventions: DRUG: Gadolinium For abdomen|DRUG: Gadolinium For abdomen|DRUG: Gadolinium For abdomen|DRUG: Gadolinium For lower back|DRUG: Gadolinium For lower back|DRUG: Gadolinium For lower back|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 12|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 24|DRUG: Efficacy of Gammagard subcutaneously at Week 36|DRUG: Efficacy of Gammagard subcutaneously at Week 36|DRUG: Efficacy of Gammagard subcutaneously at Week 36|DRUG: Efficacy of Gammagard subcutaneously at Week 36|DRUG: Efficacy of Gammagard subcutaneously at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 12|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 24|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Efficacy of Gammagard subdermally at Week 36|DRUG: Adverse Reactions of Gammagard subcutaneously at Week 12|DRUG: Adverse Reactions of Gammagard subcutaneously at Week 24|DRUG: Adverse Reactions of Gammagard subcutaneously at Week 36|DRUG: Adverse Reactions of Gammagard subdermally at Week 12|DRUG: Adverse Reactions of Gammagard subdermally at Week 24|DRUG: Adverse Reactions of Gammagard subdermally at Week 36
Study Type: INTERVENTIONAL
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT